OncoMatch/Clinical Trials/NCT06711185
Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy
Is NCT06711185 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Dapagliflozin 10 mg for breast cancer.
Treatment: Dapagliflozin 10 mg — Prospective, randomized, double-blind, controlled clinical trial to compare the effect of 9 months of treatment with dapagliflozin vs. placebo on anthracycline-induced cardiotoxicity in patients with breast cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Demographics
Lab requirements
Kidney function
glomerular filtration rate >= 30 ml/min/1.73 m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06711185 currently recruiting?
Yes, this trial is currently recruiting patients.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages